Excipy uses proprietary machine learning to redesign the formulation of existing medicines, targeting adverse reactions caused by excipients or delivery mechanisms in 5‑10% of patients. Its algorithmic platform predicts toxic interactions and creates new, safer drug versions without changing the active ingredient, enabling accelerated FDA 505(b)(2) regulatory pathways and reducing clinical risk for pharmaceutical partners.
Funding
Funding not disclosed
Founders
Product
Problem
Many approved medicines contain inactive ingredients (excipients) that cause severe adverse reactions in 5‑10% of patients with specific genetic or metabolic sensitivities, leaving a large population unable to use life‑saving therapies.
Solution
Excipy applies a proprietary machine‑learning platform to map interactions among active pharmaceutical ingredients, excipients, and human metabolic pathways. By predicting excipient‑related adverse reactions computationally, the system designs new formulations of existing drugs that remove the offending excipients while preserving therapeutic efficacy. Because the active ingredient remains unchanged, the reformulated products qualify for accelerated FDA 505(b)(2) pathways, reducing the need for early‑phase clinical trials and shortening time‑to‑market. The approach de‑risks development, expands the addressable market for proven drugs, and aims to lower the overall cost burden of adverse drug events.
Target Audience
Primary customers are pharmaceutical companies seeking to extend the market reach of existing drugs and reduce regulatory risk, as well as contract research organizations developing precision‑focused formulations for genetically sensitive patient groups.
Features
- AI-driven modeling of drug‑excipient‑metabolism interactions to identify toxicity triggers
- Automated generation of alternative formulations that eliminate harmful excipients without altering the active ingredient
- Validation pipeline optimized for FDA 505(b)(2) regulatory submissions, bypassing extensive Phase I/II studies
- Scalable data infrastructure that supports rapid reformulation of multiple blockbuster therapeutics
- Integration of pharmacogenomic data to target patient subpopulations with known genetic or metabolic variants